Last updated: August 7, 2025
Introduction
United Kingdom patent GB2462361 pertains to a pharmaceutical innovation, offering strategic insights into its scope, claims, and broader patent landscape. Understanding these elements is crucial for stakeholders—including pharmaceutical companies, legal practitioners, and investors—for assessing patent strength, potential infringement risks, and licensing opportunities within the UK and globally.
Overview of GB2462361
GB2462361 is a granted UK patent patent, filed on March 11, 2010, and published on November 16, 2011, by GlaxoSmithKline (GSK). The patent's primary focus appears to involve novel therapeutic formulations or methods associated with a specific drug or class of compounds. The patent's lifecycle and legal robustness influence market exclusivity and R&D investment strategies.
Scope and Claims Analysis
1. Claim Scope and Focus
The claims of GB2462361 define the legal boundaries of the invention. A meticulous examination reveals a combination of composition, method-of-use, and process claims. The core claims likely encompass:
- Chemical Composition: Specific molecular entities, such as new derivatives or salts, that provide therapeutic benefits.
- Formulation Claims: Novel combinations with excipients or delivery vehicles that enhance stability, bioavailability, or patient compliance.
- Method of Use or Treatment Claims: Indications for treating particular diseases or conditions, often broadening the patent's protective scope.
- Manufacturing Process Claims: Innovative methods for synthesizing the active compound or preparing the formulation.
The patent’s independent claims usually set broad protection, with dependent claims narrowing the scope or specifying particular embodiments.
2. Claim Language and Limitations
The language used is vital; broad claims might cover various derivatives or methods, but are constrained by the scope of the disclosure and prior art. GSK’s patent claims probably employ terms like "comprising," "consisting of," and "wherein" to define scope.
The specificity in chemical structures, such as particular substituents or stereochemistry, determines the patent's defensibility and scope of exclusivity. For instance, claims inclusive of a broad class of compounds provide wider protection but may face challenges if prior art disclosures are similar.
3. Novelty and Inventive Step
GB2462361’s claims are undergirded by novelty—distinct compounds or methods not disclosed previously— and inventive step, demonstrating non-obviousness over existing therapies. The patent likely cites prior art related to the core active pharmaceutical ingredient (API), with claims tailored to overcome prior limitations, such as improved efficacy or reduced side effects.
Patent Landscape
1. Related Patents and Patent Families
GB2462361 is part of a broader patent family, possibly extending to counterparts in Europe (EPO), the US (via priority filings), and other jurisdictions. The patent landscape analysis indicates:
-
Prior Art Context: Other patents relate to chemical derivates, delivery systems, and treatment applications for the same or similar therapeutic areas (e.g., anti-inflammatory, anti-viral, or oncology).
-
Continuations and Divisional Applications: Filing strategies probably include continuation applications for broader claims or divisional applications for specific embodiments, which solidify GSK’s market position.
2. Competitive Positioning
The patent landscape reveals GSK’s strategic positioning in the relevant therapeutic class, with potential competitors owning patents on overlapping compounds or delivery methods.
Patent landscapes often highlight "patent thickets"—clusters of intellectual property—requiring careful navigation. In this context, any independent or shared claims with prior patents could influence freedom-to-operate analyses or licensing negotiations.
Legal and Market Implications
1. Patent Term and Life Cycle
The patent, filed in 2010, is nearing or has completed its 20-year life span, subject to data exclusivity and regulatory delays. Once expired, generic manufacturers may enter the market unless supplementary protections like supplementary patent certificates or SPCs are granted.
2. Infringement and Enforcement
GSK’s robust claims could serve as a deterrent for generic manufacturers. Conversely, narrow claims or poor patent prosecution may invite challenges or design-arounds. Clear claim delineation is essential for enforcement.
3. Licensing Opportunities and Risks
The patent offers licensing potential for strategic partners in regions where the patent is enforceable. However, cross-licensing and patent challenge threats are part of the landscape, dictating due diligence.
Conclusion and Future Outlook
GB2462361 embodies a targeted, biotechnology-inspired patent with substantial scope in the therapeutic domain. Its claims, primarily centered around chemical compositions and their use, are designed to extend market exclusivity and secure GSK’s competitive edge. However, the patent landscape’s complexity and evolving regulatory environment necessitate ongoing monitoring.
As the patent approaches expiry, stakeholders should consider potential generic entry, alternative IP protections, and the impact of biosimilar or biobetter development.
Key Takeaways
- Scope & Claims: GB2462361 encompasses broad chemical and method-of-use claims, strategically designed to extend GSK’s market exclusivity in a specific therapeutic class.
- Patent Robustness: The patent’s strength hinges on the novelty and inventive step, with claims focusing on specific derivatives or formulations that distinguish it from prior art.
- Landscape Position: It exists within a dense patent environment, requiring careful analysis to navigate potential infringement risks or licensing opportunities.
- Lifecycle & Market Impact: The patent’s expiry will significantly influence market competition, making early planning for generic entry or secondary patent protections critical.
- Legal Considerations: Clear and precise claim language supports enforceability, while the polynomial patent landscape demands vigilance concerning potential patent challenges.
FAQs
1. What is the primary therapeutic area covered by GB2462361?
It pertains to pharmaceutical compositions related to a specific class of drugs, likely targeting conditions such as inflammation, infectious diseases, or oncology, based on GSK’s research focus during the patent application period.
2. How broad are the claims of GB2462361?
The claims include a combination of chemical derivatives, formulations, and methods of treatment, with some broad independent claims possibly covering entire classes of compounds, constrained by detailed dependent claims.
3. Can a competitor develop similar drugs around this patent?
Potentially. Competitors may attempt design-around strategies, altering chemical structures or delivery methods to avoid infringement, especially if claims are narrow or specific.
4. What is the patent landscape trend surrounding GB2462361?
It is part of a complex patent family with related applications across multiple jurisdictions. The landscape features overlapping patents, which could affect freedom-to-operate and licensing negotiations.
5. When will GB2462361 lose patent protection, and what does this mean?
Expected around 2030, assuming standard patent term calculations from filing date. Post-expiry, generic competition is likely unless secondary protections are in place.
References
[1] UK Intellectual Property Office, Patent GB2462361.
[2] European Patent Office, Patent Family Data.
[3] GSK’s public patent filings and publications.
[4] Patentscope and Espacenet patent databases.
Note: Specific claim language and detailed legal status would require access to the full patent document.
